Meksidol tab n / 125mg film about 30 pc

Description

Composition
Active substance:
emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) – 125.0 mg.
Excipients:
Lactose monohydrate – 97.5 mg; Povidone – 25.0 mg; magnesium stearate – 2.50 mg.
Film coating: Opadry II White 33G28435 – 7,5 mg (Hypromellose – 3.0 mg of titanium dioxide – 1.875 mg lactose monohydrate – 1,575 mg, polyethylene glycol (macrogol) – 0.6 mg, triacetin – 0.45 mg).
Description:
round tablets, biconvex shaped, film-coated, white to white with Valium color.
Product form:
Tablets, film-coated, 125 mg. 10 tablets in blisters of PVC film and aluminum foil. 3 blisters together with instructions for use in a pile of cardboard.
Contraindications
Acute hepatic and / or renal insufficiency, increased individual sensitivity to the drug. Due to insufficient knowledge of the drug – the children’s age, pregnancy, breastfeeding.
Dosage
125 mg
Indications
– the effects of stroke, including after transient ischemic attacks, in phase subcompensation as prevention courses;
– mild traumatic brain injury, the effects of traumatic brain injury;
– encephalopathies of various origins (discirkulatornaya, dysmetabolic, posttraumatic mixed);
autonomic dystonia syndrome;
– mild cognitive disorders of atherosclerotic;
– Anxiety disorders in neurotic and neurosis-like states;
– coronary heart disease in the complex therapy;
– relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetative-vascular disorders, postabstinentnom disorder;
– states after acute intoxication antipsychotics;
– asthenic conditions, as well as for the prevention of systemic diseases under the influence of extreme factors and loads;
– exposure to extreme (stress) factors.
Interaction with other drugs
MEXIDOL® combined with all drugs used for the treatment of systemic diseases. It increases the effects of benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants and antiparkinsonian. It reduces the toxic effects of ethanol.
Overdose
with an overdose may develop drowsiness.
pharmachologic effect
Pharmacological group:
Anti-oxidant agent.
Pharmacodynamics:
MEXIDOL® is an inhibitor of free radical processes, membrane protectors having antihypoxic, stress-protective, neuroprotective, anticonvulsant and anxiolytic effects. The preparation increases the body’s resistance to the damaging effects of various factors (shock, hypoxia and ischemia, cerebrovascular accident, alcohol intoxication and antipsychotic agents (neuroleptics)).
Mexidol action mechanism is due to its antioxidant, antihypoxic and membrane action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio lipid-protein membrane reduces viscosity and increases its fluidity. MEXIDOL® modulates the activity of membrane-associated enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, promotes preservation of structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. MEXIDOL® increases in the brain, dopamine. Causes increased activation of compensatory aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, energosinteziruyuschih activation of mitochondrial functions, stabilization of cell membranes.
The drug metabolism and improves blood flow to the brain, improves microcirculation and blood rheology, reduce platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets) for hemolysis. It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Anti-stress effect is the normalization of post-stress behavior, somatovegetativnyh violations, restoration of the sleep-wake cycles, broken processes of learning and memory, and reducing degenerative morphological changes in different brain structures.
MEXIDOL® has a pronounced effect when antitoxic withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral, autonomic functions, and is able to remove the cognitive impairment caused by prolonged use of ethanol and its abolition. Influenced Mexidol amplified tranquilizing action, neuroleptics, antidepressants, hypnotics and anticonvulsants, to reduce their dose and reduce side effects. MEXIDOL® improves the functional state of ischemic myocardium. In the context of coronary insufficiency increases collateral blood flow to ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintaining their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction.
Pharmacokinetics:
Quickly absorbed by ingestion. The maximum concentration at doses of 400-500 mg of 3.5-4.0 g / ml. Rapidly distributed to organs and tissues. The average retention time of the drug in the body by ingestion – 4.9-5.2 hours. It is metabolized in the liver by glyukuronkonyugirovaniya. 5 metabolites have been identified: 3-hydroxypyridine phosphate produced in the liver and involvement of alkaline phosphatase decomposes to phosphoric acid, and 3-hydroxypyridin; 2nd metabolite – a pharmacologically active, is formed in large quantities and is found in the urine 1-2 hours after administration; Third – is displayed in large amounts in the urine; 4 th and 5 th – glyukuronkonyugaty. T1 / 2 when taken orally – 2.0-2.6 hours. Rapidly excreted in the urine primarily as metabolites in small quantities – unchanged. The most intense output in the first 4 hours after ingestion. Indicators excretion in the urine unchanged drug and metabolites have individual variability.
Conditions of supply of pharmacies
on prescription.
side effects
possible occurrence of individual adverse reactions or dyspeptic dyspeptic nature of allergic reactions.
special instructions
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
stored in a dry, dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside, in the 125-250 mg 3 times a day; maximum daily dose – 800 mg (6 tablets). The duration of the treatment – 2-6 weeks; for the relief of alcohol withdrawal – 5-7 days. Treatment stopped gradually reducing the dose for 2-3 days.
Starting dose – 125-250 mg (1-2 tablets) 1-2 times a day with gradual increase until a therapeutic effect; maximum daily dose – 800 mg (6 tablets).
Duration of therapy in patients with coronary heart disease, at least 1,5-2 months. Repeated courses (on doctor’s advice), preferably carried out in the spring and autumn periods.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist